Humacyte annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Humacyte Depreciation & Amortization Growth & History (HUMA)
Humacyte's depreciation and amortization was $7.3M for fiscal 2025.
View full Humacyte company overviewHumacyte annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.3M | $155,000 | +2.16% |
| 2024 | 2024-12-31 | $7.2M | −$529,000 | −6.85% |
| 2023 | 2023-12-31 | $7.7M | −$491,000 | −5.98% |
| 2022 | 2022-12-31 | $8.2M | −$31,000 | −0.38% |
| 2021 | 2021-12-31 | $8.2M | −$110,000 | −1.32% |
| 2020 | 2020-12-31 | $8.4M | — | — |
Humacyte quarterly depreciation and amortization
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.8M | −$37,000 | −2.03% |
| Q1 2026 | 2026-03-31 | $1.8M | −$42,000 | −2.29% |
| Q4 2025 | 2025-12-31 | $1.8M | — | — |
| Q3 2025 | 2025-09-30 | $1.8M | $2,000 | +0.11% |
| Q2 2025 | 2025-06-30 | $1.8M | $0 | 0.00% |
| Q1 2025 | 2025-03-31 | $1.8M | $41,000 | +2.29% |
| Q3 2024 | 2024-09-30 | $1.8M | $7,000 | +0.39% |
| Q2 2024 | 2024-06-30 | $1.8M | −$192,000 | −9.53% |
| Q1 2024 | 2024-03-31 | $1.8M | −$282,000 | −13.60% |
| Q3 2023 | 2023-09-30 | $1.8M | −$200,000 | −9.93% |
| Q2 2023 | 2023-06-30 | $2.0M | $1,000 | +0.05% |
| Q1 2023 | 2023-03-31 | $2.1M | $33,000 | +1.62% |
| Q3 2022 | 2022-09-30 | $2.0M | $0 | 0.00% |
| Q2 2022 | 2022-06-30 | $2.0M | −$101,000 | −4.78% |
| Q1 2022 | 2022-03-31 | $2.0M | −$30,000 | −1.45% |
| Q3 2021 | 2021-09-30 | $2.0M | $415,000 | +25.94% |
| Q2 2021 | 2021-06-30 | $2.1M | — | — |
| Q1 2021 | 2021-03-31 | $2.1M | — | — |
| Q3 2020 | 2020-09-30 | $1.6M | — | — |
Humacyte depreciation and amortization trends
Over the last five fiscal years, Humacyte's depreciation and amortization decreased from $8.4M to $7.3M, a change of −$1.0M. The latest reported quarter, Q2 2026, shows $1.8M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Humacyte source filings ↗